Skip to: [Content] [Navigation]

LBT Innovations Wins Prestigious International Medical Award
The award highlights PREVI Isola’s breakthrough technology for microbiology testing
LBT CEO to accept award at formal ceremony in New York City in June

Adelaide, South Australia (April 9, 2010) - An Australian medical innovation has won a major international medical excellence design award.

The breakthrough PREVI™ Isola – a revolutionary technology for streaking agar plates in microbiology laboratories – has been developed by Adelaide-based LBT Innovations Ltd (ASX: LBT). This cutting edge robotic system replaces over a hundred years of manual streaking of specimens on to agar plates by individuals.

The company and its international partner bioMérieux launched the system worldwide in 2008. It has now been awarded a prize in the 2010 MDEA Medical Design Excellence Awards, a premier U.S. accolade for the international medical technology community for contributions and advances in the design of medical products.

LBT Innovations’ chief executive officer Ms Lusia Guthrie said the award was fitting recognition for the technology, which had substantially improved scientific workplaces where it was installed.

“It is imperative that microbiology laboratories meet the changing needs of growing populations and growing demand,” she said.  “PREVI™ Isola capitalises on the estimated 20 per cent workload increase demanded of modern laboratories.”

LBT worked with bioMérieux, the world leader in diagnostics for the microbiology lab, to adapt the new technology and commercialise it to the company’s global customer base. Mr Stéphane Bancel, bioMérieux chief executive officer, said, “Our ambition is to provide the most innovative technologies available to accelerate and streamline microbiology lab workflow.”

“PREVI Isola is a key part of bioMérieux’s Full Microbiology Lab Automation offer and we would like to congratulate LBT for this award, which confirms the excellence of the design.”

“This instrument substantially increases the speed, accuracy and efficiency of microbiology labs. This is a breakthrough for microbiology, a major step change, and this view is endorsed by the judges of the MDEA Awards.”

PREVI™ Isola is now being installed in laboratories around the globe in the U.S., Europe, Asia and Latin America.  It is expected to be installed in Australian laboratories from this year.

The technology is based on an invention by Adelaide scientist John Glasson and engineer Lachlan Smith who realised “there had to be a better way” to address the challenges facing modern microbiology laboratories.

The MDEA Award will be officially presented in a ceremony at the Medical Design & Manufacturing 2010 Conference and Exposition in New York in June. Lusia Guthrie will accept the award on behalf of LBT Innovations.

--ENDS—

About the Medical Design Excellence Awards
The Medical Design Excellence Awards competition (MDEAwards.com) is organized and presented by Canon Communications LLC (Los Angeles) and is the only awards program that exclusively recognizes contributions and advances in the design of medical products. Entries are evaluated on the basis of their design and engineering features, including innovative use of materials, user-related functions that improve healthcare delivery and change traditional medical attitudes or practices, features that provide enhanced benefits to the patient, and the ability of the product development team to overcome design and engineering challenges so that the product meets its clinical objectives.

A comprehensive review of the entries was performed by an impartial, multidisciplinary panel of third-party jurors with expertise in biomedical engineering, human factors, industrial design, medicine, and diagnostics.

About LBT Innovations
LBT Innovations (ASX: LBT) is changing the way microbiology labs around the world operate.  Based in Adelaide South Australia, its lead product is the PREVI™ Isola system, which incorporates LBT’s unique Australian designed MicroStreak® technology for the automation of plate streaking and processing.  This means quicker and more accurate test results and better patient outcomes.

PREVI™ Isola is being sold around the world by LBT Innovations’ international partner bioMérieux.

LBT Innovations plans to commercialise further products that substantially improve the efficiency and accuracy of pathology testing in laboratories worldwide.

www.lbtinnovations.com

CONTACTS

LBT Innovations

Media Relations

Lusia Guthrie
CEO & MD
Tel: +61 (0)8 8227 1555
E: info@lbtinnovations.com

Emma Power / Rudi Michelson
Monsoon Communications
Tel: +61 (0)3 9620 3333
E: emmap@monsoon.com.au